Mutations in cyclin-dependent kinase inhibitor p16 and Smad4, a downstream target of transforming growth factor β, also exhibit high mutation frequencies in pancreatic tumors [13]. This evidence concerns the gene CDKN2A and pancreatic neoplasm.